Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

1997 • 897 citations

Design and Analysis of Phase I Clinical Trials

1989 • 882 citations

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

1990 • 813 citations

Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]

1992 • 507 citations

Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

1995 • 458 citations

Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

1985 • 410 citations

Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity

1991 • 407 citations

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

1991 • 388 citations

MDR1 Gene Expression and Treatment Outcome in Acute Myeloid Leukemia

1991 • 372 citations

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.

1985 • 366 citations

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

1991 • 364 citations

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

1992 • 298 citations

Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia

1989 • 294 citations

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

1993 • 284 citations

Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group

1990 • 276 citations

Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases

1995 • 229 citations

Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.

1988 • 222 citations

MDR₁ transcript levels as an indication of resistant disease in acute myelogenous leukaemia

1990 • 184 citations

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

1996 • 179 citations

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

1999 • 152 citations

Phase I clinical trials.

1977 • 127 citations

Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype

1991 • 126 citations

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

1999 • 122 citations

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study

1996 • 119 citations

Comparative Study on Reversal Efficacy of SDZ PSC 833, Cyclosporin a and Verapamil on Multidrug Resistance in vitro and in vivo

1995 • 107 citations

Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia

1993 • 105 citations

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.

1997 • 95 citations

Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity

1995 • 93 citations

Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833

1995 • 83 citations

Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo.

1988 • 71 citations

A Successful System of Scientific Data Audits for Clinical Trials

1993 • 71 citations

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.

1996 • 59 citations

Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL

1994 • 55 citations

Chromosomal location of human P-glycoprotein gene sequences

1987 • 43 citations

SDZ PSC 833 and SDZ 280–446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells

1992 • 20 citations

Cited By (0)

Loading...